{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:43:11Z","timestamp":1777970591859,"version":"3.51.4"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>With global aging accelerating, cancer incidence among older adults is rapidly increasing. Individuals aged \u226565 years now represent 64% of new cancer cases and 71.3% of cancer-related deaths worldwide. This population exhibits a distinct immune imbalance\u2014driven by tumor-induced immunosuppression, immunosenescence, and inflammaging\u2014which contributes to poor tolerance of standard therapies and suboptimal outcomes with PD-1\/PD-L1 inhibitors.<\/jats:p><jats:p>As an emerging immunotherapeutic strategy, oncolytic viruses (OVs) selectively infect tumor cells, induce immunogenic cell death (ICD), and activate the cGAS\u2013STING pathway. Although clinical data in elderly patients with esophageal, lung, or pancreatic cancer are scarce, promising outcomes have been reported in melanoma\/sarcoma subgroups, including objective response rates of 26.4\u201332.9% and a median duration of response of 33.7 months, highlighting the potent antitumor potential of OVs.<\/jats:p><jats:p>However, age-related immunological vulnerability\u2014manifesting across different frailty stages as reflected by G8 scoring\u2014may predispose elderly patients to immune overload, cytokine storm, and impaired tolerance, while this group remains underrepresented in OV trials. Systematic studies in this context are lacking. This review highlights the immunological characteristics of aging, emphasizes the importance of addressing immunological vulnerability across different age stages (G8 scoring), and outlines emerging challenges and future directions for OV-based therapies tailored to frail elderly populations.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1686659","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:41:22Z","timestamp":1759902082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Oncolytic virus therapy in the elderly: immune frailty, challenges, and perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.05.002","article-title":"Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study","volume":"4","author":"Li","year":"2024","journal-title":"J\u00a0Natl Cancer Cent"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01960","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes","volume":"8","author":"Fulop","year":"2017","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: A randomized clinical trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.538174","article-title":"Efficacy of anti-PD-1\/PD-L1 monotherapy or combinational therapy in patients aged 75 years or older: A study-level meta-analysis","volume":"11","author":"Nie","year":"2021","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1591875","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"Oncoimmunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101200JCO2501346","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)","author":"Wong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103362","article-title":"Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with Malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis","volume":"86","author":"Lau","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100468","DOI":"10.1016\/j.esmoop.2022.100468","article-title":"Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study","volume":"7","author":"Baldini","year":"2022","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2022.11.005","article-title":"Age-associated remodeling of T cell immunity and metabolism","volume":"35","author":"Han","year":"2023","journal-title":"Cell Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12979-020-0174-7","article-title":"Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma","volume":"17","author":"Jeske","year":"2020","journal-title":"Immun Ageing"},{"key":"B17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-023-01426-4","article-title":"Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4772","article-title":"A novel oncolytic virus induces a regional cytokine storm and safely eliminates Malignant ascites of colon cancer","volume":"11","author":"Dong","year":"2022","journal-title":"Cancer Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1116110108","article-title":"Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age","volume":"108","author":"Pang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009302","article-title":"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment","volume":"12","author":"Azar","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: A double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(96)80012-4","article-title":"Epitope spreading","volume":"8","author":"Vanderlugt","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40780-024-00388-0","article-title":"Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)","volume":"10","author":"Hong","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0020","article-title":"Disseminated herpes infection following talimogene laherparepvec administration","volume":"158","author":"Kimmis","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108520","DOI":"10.1016\/j.mbs.2021.108520","article-title":"The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study","volume":"334","author":"Pooladvand","year":"2021","journal-title":"Math BIOSCIENCES"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0080","article-title":"Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers","volume":"13","author":"Ni","year":"2021","journal-title":"Immunotherapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814189","article-title":"Anti-tumor immunogenicity of the oncolytic virus CF33-hNIS-antiPDL1 against ex vivo peritoneal cells from gastric cancer patients","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13048-024-01464-7","article-title":"The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma","volume":"17","author":"Qin","year":"2024","journal-title":"J Ovarian Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13058-015-0541-z","article-title":"Presence of circulating Her2-reactive CD8\u2009+\u2009T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients","volume":"17","author":"Bailur","year":"2015","journal-title":"Breast Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00316","article-title":"The effect of age on thymic function","volume":"4","author":"Palmer","year":"2013","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-023-38810-0","article-title":"Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade","volume":"14","author":"Yam-Puc","year":"2023","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"104297","DOI":"10.1016\/j.cellimm.2021.104297","article-title":"MDSCs, ageing and inflammageing","volume":"362","author":"Pawelec","year":"2021","journal-title":"Cell Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cells11061017","article-title":"Aging of the immune system: focus on natural killer cells phenotype and functions","volume":"11","author":"Brauning","year":"2022","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12943-022-01679-6","article-title":"IL-6\/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction","volume":"21","author":"Meraviglia-Crivelli","year":"2022","journal-title":"Mol Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9036225","DOI":"10.1155\/2024\/9036225","article-title":"PD-L1, STAT3, IL6, and EGFR immunoexpressions in high-grade osteosarcoma","volume":"2024","author":"Rahmadiani","year":"2024","journal-title":"Adv Orthop"},{"key":"B43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: a key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114721","article-title":"Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma","volume":"43","author":"H\u00fcser","year":"2024","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1038\/s41467-025-58512-z","article-title":"Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors","volume":"16","author":"Kao","year":"2025","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of age-related thymic involution to immunosenescence and inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun Ageing"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00179-3","article-title":"Is cancer biology different in older patients","volume":"2","author":"Van Herck","year":"2021","journal-title":"Lancet Healthy Longevity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2008.21","article-title":"Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial","volume":"15","author":"White","year":"2008","journal-title":"Gene Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S350136","article-title":"In vitro characterization of enhanced human immune responses by GM-CSF encoding HSV-1-induced melanoma cells","volume":"15","author":"Delic","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010493","article-title":"Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial","volume":"13","author":"Pakola","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2019.07.003","article-title":"Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance","volume":"51","author":"Rivadeneira","year":"2019","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.12.002","article-title":"The evolution of powerful yet perilous immune systems","volume":"43","author":"Graham","year":"2022","journal-title":"Trends Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.02.003","article-title":"Metabolic programs tailor T cell immunity in viral infection, cancer, and aging","volume":"34","author":"M\u00f8ller","year":"2022","journal-title":"Cell Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix080","article-title":"CMV-specific T-cell responses at older ages: broad responses with a large central memory component may be key to long-term survival","volume":"215","author":"Bajwa","year":"2017","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.12.8218","article-title":"Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion","volume":"175","author":"Fletcher","year":"2005","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301721","article-title":"Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans","volume":"192","author":"Wertheimer","year":"2014","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2645","article-title":"Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly","volume":"176","author":"Hadrup","year":"2006","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.46","article-title":"Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity","volume":"34","author":"Cao","year":"2015","journal-title":"Oncogene"},{"key":"B66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1034\/j.1600-065X.2003.00051.x","article-title":"Activation-induced cell death in T cells","volume":"193","author":"Green","year":"2003","journal-title":"Immunol Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1038\/s41467-023-39683-z","article-title":"Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279387","article-title":"A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses","volume":"14","author":"Smith","year":"2023","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04510-3","article-title":"Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma","volume":"149","author":"Lutzky","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e002224","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J immunotherapy Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41419-018-0325-3","article-title":"Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer","volume":"9","author":"Hu","year":"2018","journal-title":"Cell Death Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/v11080762","article-title":"Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms","volume":"11","author":"Smatti","year":"2019","journal-title":"Viruses"},{"key":"B76","doi-asserted-by":"publisher","first-page":"22733","DOI":"10.1038\/s41598-025-06314-0","article-title":"Real world pharmacovigilance study of antineoplastic drug related vitiligo risks","volume":"15","author":"Yang","year":"2025","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02151","article-title":"Development of CD73 inhibitors in tumor immunotherapy and opportunities in imaging and combination therapy","volume":"68","author":"Bi","year":"2025","journal-title":"J Med Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212209","article-title":"Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy","volume":"14","author":"Kurago","year":"2023","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0409","article-title":"Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses","volume":"13","author":"Fricke","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI38052","article-title":"Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment","volume":"119","author":"Levy","year":"2009","journal-title":"J Clin Invest"},{"key":"B84","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","article-title":"mTOR inhibition improves immune function in the elderly","volume":"6","author":"Mannick","year":"2014","journal-title":"Sci Transl Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12979-023-00394-0","article-title":"The effect of metformin on senescence of T lymphocytes","volume":"20","author":"Yang","year":"2023","journal-title":"Immun Ageing"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Advances"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0116","article-title":"Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function","volume":"12","author":"Wei","year":"2020","journal-title":"Immunotherapy"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e25786","DOI":"10.1097\/MD.0000000000025786","article-title":"Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report","volume":"100","author":"Zi","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12091010","article-title":"Dose considerations for vaccinia oncolytic virus based on retrospective reanalysis of early and late clinical trials","volume":"12","author":"Cyrelle Ornella","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","article-title":"An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells","volume":"53","author":"Kumagai","year":"2020","journal-title":"Immunity"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury","volume":"21","author":"Velardi","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1022808","article-title":"IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2024.12.005","article-title":"Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design","volume":"118","author":"Salem","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaf019","article-title":"Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report","volume":"9","author":"Wadden","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"188526","DOI":"10.1016\/j.bbcan.2021.188526","article-title":"Delivery routes matter: Safety and efficacy of intratumoral immunotherapy","volume":"1875","author":"De Lombaerde","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010543","article-title":"Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1\/2 trial","volume":"13","author":"Tan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e2235714","DOI":"10.1001\/jamanetworkopen.2022.35714","article-title":"Clinical trial enrollment, ineligibility, and reasons for decline in older vs younger patients with cancer in the national cancer institute community oncology research program","volume":"5","author":"Sedrak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00442","article-title":"How is geriatric assessment used in clinical practice for older adults with cancer? A survey of cancer providers by the american society of clinical oncology","volume":"17","author":"Dale","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01007","article-title":"Impact of geriatric assessment and management on quality of life, unplanned hospitalizations, toxicity, and survival for older adults with cancer: the randomized 5C trial","volume":"41","author":"Puts","year":"2023","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1161\/JAHA.123.032620","article-title":"Immune checkpoint inhibitors and cardiotoxicity: A comparative meta-analysis of observational studies and randomized controlled trials","volume":"13","author":"Sharma","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab125","article-title":"Glioblastoma as an age-related neurological disorder in adults","volume":"3","author":"Kim","year":"2021","journal-title":"Neuro-Oncology Adv"},{"key":"B112","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"14975","DOI":"10.1038\/s41598-024-65907-3","article-title":"Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma","volume":"14","author":"Jacquerie","year":"2024","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1714478115","article-title":"Thymic involution and rising disease incidence with age","volume":"115","author":"Palmer","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.917972","article-title":"Aging affects the role of myeloid-derived suppressor cells in alloimmunity","volume":"13","author":"Schroeter","year":"2022","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.critrevonc.2007.03.002","article-title":"Aging and the dendritic cell system: implications for cancer","volume":"64","author":"Shurin","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.04.008","article-title":"Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans","volume":"24","author":"Solana","year":"2012","journal-title":"Semin Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00318","article-title":"B cell dysfunction associated with aging and autoimmune diseases","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e003217","DOI":"10.1136\/jitc-2021-003217","article-title":"Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment","volume":"9","author":"Ma","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00896","article-title":"Role of dendritic cells in inflammation and loss of tolerance in the elderly","volume":"8","author":"Agrawal","year":"2017","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","article-title":"How the ageing microenvironment influences tumour progression","volume":"20","author":"Fane","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/nature17392","article-title":"sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance","volume":"532","author":"Kaur","year":"2016","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1483806","article-title":"Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients","volume":"15","author":"Raimondi","year":"2024","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.omto.2019.02.002","article-title":"The antiviral apparatus: STING and oncolytic virus restriction","volume":"13","author":"Lee","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B129","doi-asserted-by":"publisher","first-page":"108469","DOI":"10.1016\/j.intimp.2021.108469","article-title":"Immunotherapy of cancer by targeting regulatory T cells","volume":"104","author":"Chen","year":"2022","journal-title":"Int Immunopharmacology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e003488","DOI":"10.1136\/jitc-2021-003488","article-title":"Vectorized Treg-depleting \u03b1CTLA-4 elicits antigen cross-presentation and CD8(+) T cell immunity to reject \u2018cold\u2019 tumors","volume":"10","author":"Semmrich","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3061","article-title":"Induced vitiligo due to talimogene laherparepvec injection for metastatic melanoma associated with long-term complete response","volume":"99","author":"Iglesias","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1272351","article-title":"Recent progress in combination therapy of oncolytic vaccinia virus","volume":"15","author":"Mirbahari","year":"2024","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.101","article-title":"Sex steroid ablation: an immunoregenerative strategy for immunocompromised patients","author":"Velardi","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1686659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:41:23Z","timestamp":1759902083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1686659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":133,"alternative-id":["10.3389\/fimmu.2025.1686659"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1686659","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1686659"}}